Importance of left atrial diameter and atrial fibrillatory frequency for conversion of persistent atrial fibrillation with oral flecainide.
Bollmann
Andreas
A
Department of Cardiology, University Hospital Magdeburg, Magdeburg, Germany. andreas.bollmann@medizin.uni-magdeburg.de
Binias
Karl-Heinz
KH
Toepffer
Ines
I
Molling
Jochen
J
Geller
Christoph
C
Klein
Helmut U
HU
D000284:Administration, Oral; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000628:therapy*; D004341:Drug Evaluation; D004452:Echocardiography; D004554:Electric Countershock; D004562:Electrocardiography; D005260:Female; D005424:Flecainide / Q000008:administration & dosage* / Q000627:therapeutic use*; D006325:Heart Atria / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology*; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D005424:Flecainide